HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

MEDI0641

antibody-drug conjugate that consists of pyrrolobenzodiazepine (PBD) dimer conugated to antibody against 5T4 oncofetal antigen

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hollingsworth, Robert E: 2 articles (05/2017 - 01/2017)
2.	Hurt, Elaine M: 2 articles (05/2017 - 01/2017)
3.	Tice, David A: 2 articles (05/2017 - 01/2017)
4.	Finkel, Kelsey A: 1 article (05/2017)
5.	Kerk, Samuel A: 1 article (05/2017)
6.	Nör, Felipe: 1 article (05/2017)
7.	Nör, Jacques E: 1 article (05/2017)
8.	Pearson, Alexander T: 1 article (05/2017)
9.	Vargas, Pablo A: 1 article (05/2017)
10.	Wagner, Vivian P: 1 article (05/2017)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2017 - "Taken together, these preclinical data support further development of 5T4-PBD, also known as MEDI0641, against 5T4+ cancer indications. " 05/15/2017 - "Treatment with MEDI0641 caused a significant reduction in the CSC fraction in HNSCC cells (UM-SCC-11B, UM-SCC-22B) in vitro Notably, a single intravenous dose of 1 mg/kg MEDI0641 caused long-lasting tumor regression in three patient-derived xenograft (PDX) models of HNSCC. " 05/15/2017 - "Importantly, mice (n = 12) treated with neoadjuvant, single administration of MEDI0641 prior to surgical tumor removal showed no recurrence for more than 200 days, whereas the control group had 7 recurrences (in 12 mice; P = 0.0047).Conclusions: Collectively, these findings demonstrate that an anti-5T4 antibody-drug conjugate reduces the fraction of CSCs and prevents local recurrence and suggest a novel therapeutic approach for patients with HNSCC. "
2.	Squamous Cell Carcinoma of Head and Neck 05/15/2017 - "Treatment with MEDI0641 caused a significant reduction in the CSC fraction in HNSCC cells (UM-SCC-11B, UM-SCC-22B) in vitro Notably, a single intravenous dose of 1 mg/kg MEDI0641 caused long-lasting tumor regression in three patient-derived xenograft (PDX) models of HNSCC. " 05/15/2017 - "Importantly, mice (n = 12) treated with neoadjuvant, single administration of MEDI0641 prior to surgical tumor removal showed no recurrence for more than 200 days, whereas the control group had 7 recurrences (in 12 mice; P = 0.0047).Conclusions: Collectively, these findings demonstrate that an anti-5T4 antibody-drug conjugate reduces the fraction of CSCs and prevents local recurrence and suggest a novel therapeutic approach for patients with HNSCC. " 05/15/2017 - " Design: Here, we evaluated the efficacy of MEDI0641, a novel antibody-drug conjugate targeted to 5T4 and carrying a DNA-damaging "payload" (pyrrolobenzodiazepine) in preclinical models of HNSCC.Results"

Related Drugs and Biologics

1.	A-Form DNA (A-DNA)
2.	Immunoconjugates (Immunoconjugate)
3.	pyrrolo(2,1-c)(1,4)benzodiazepine